Latest Breaking News On - Dorisk hansen - Page 1 : comparemela.com

A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.

United statesDorisk hansenAmerican society of hematologyNational comprehensive cancer networkMoffitt cancer center research institute in tampaMoffitt cancer centerResearch instituteAmerican societyMultiple myelomaPlasma cell myelomaMonoclonal antibodyBiologic therapyProteasome inhibitorTransplantation of stem cellsRansplantation of hematopoietic stem cellsHematopoietic stem cell transplant